Skip to main content
SpringerLink
Log in

Anticorps anti-EGFR

  • Chapter
Les thérapies ciblées

Part of the book series: Oncologie pratique ((ONCOLPRAT))

  • 379 Accesses

Abstrait

Le récepteur du facteur de croissance épidermique (EGFR) est une glycoprotéine transmembranaire de 170 kDA, membre de la famille des récepteurs ErbB (ou HER) à activité tyrosine kinase. La structure de ľEGFR comporte trois domaines distincts: un domaine extra-cellulaire (621 acides aminés), site de fixation du ligand, un domaine hydrophobe transmembranaire (23 acides aminés) permettant ľancrage du récepteur dans la membrane plasmique, et un domaine intracellulaire à activité tyrosine kinase (542 acides aminés). Ľactivité tyrosine kinase nécessite la fixation ďun phosphore sur un des sites majeurs ďautophosphorylation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Cunningham D, Humblet Y, Siena S, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–45

    Article  PubMed  CAS  Google Scholar 

  2. Saltz LB, Meropol NJ, Loehrer PJSr, et al. (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 1201–8

    Article  PubMed  CAS  Google Scholar 

  3. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24: 4914–21

    Article  PubMed  CAS  Google Scholar 

  4. Andre T, Tabernero J, Van Cutsem E, et al. (2007) Phase II study with cetuximab plus FOLFOX-4 in first-line setting for epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC): Final results. Gastrointestinal Cancers symposium: abstract 334

    Google Scholar 

  5. Peeters M, Raoul JL, van Laethem JL, et al. (2005) Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC). Eur J Cancer (suppl 3): abstract 664

    Google Scholar 

  6. Bonner JA, Harari PM, Giralt J, et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 9: 567–78

    Article  Google Scholar 

  7. Herbst RS, Arquette M, Shin DM, et al. (2005) Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23: 5578–87

    Article  PubMed  CAS  Google Scholar 

  8. Baselga J, Trigo JM, Bourhis J, et al. (2005) Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23: 5568–77

    Article  PubMed  CAS  Google Scholar 

  9. Hanna N, Lilenbaum R, Ansari R, et al. (2006) Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 20: 5253–8

    Article  Google Scholar 

  10. Rosell R, Daniel C, Ramlau R, et al. (2004) Randomized phase II study of cetuximab in combination with cisplatin (c) and vinorelbine (V) vs CV alone in the first-line treatment of patients (pts) with epidermal growth factor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 22 (suppl 14): abstract 7012a

    Google Scholar 

  11. Berlin J, Neubauer M, Swanson P, et al. (2006) Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing >10% epidermal growth factor receptor (EGFr). J Clin Oncol 24 (suppl 18s): abstract 3548

    Google Scholar 

  12. Hecht J, Mitchell E, Baranda J (2006) Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1–9%) or negative (<1%) levels of epidermal growth factor receptor (EGFr). J Clin Oncol 24 (Supplement 18s): abstract 3547

    Google Scholar 

  13. Malik I, Hecht JR, Patnaik A, et al. (2005) Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 23 (suppl 16s): abstract 3520

    Google Scholar 

  14. Peeters M, Van Cutsem E, Siena S, et al. (2006) A phase 3,multicenter, randomized controlled trial of panitumumab plus best supportive care (BSC) versus BSC alone in patients with metastatic colorectal cancer. Proc Am Ass Cancer Res

    Google Scholar 

  15. Vanhoefer U, Tewes M, Rojo F, et al. (2004) Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 22: 175–84

    Article  PubMed  CAS  Google Scholar 

  16. Graeven U, Kremer B, Südhoff Th, et al. (2006) Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br J Cancer 94: 1293–99

    Article  PubMed  CAS  Google Scholar 

  17. Kollmannsberger C, Schittenhelm M, Honecker F, et al. (2006) A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol 17: 1007–13

    Article  PubMed  CAS  Google Scholar 

  18. Van Cutsem E, Humblet Y, Gelderblom H, et al. (2007) Cetuximab dose-escalation study in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic and efficacy data of a randomized study. Gastrointestinal Cancers symposium: abstract 237

    Google Scholar 

  19. Saltz LB, Lenz H, Hochster H, et al. (2005) Randomized Phase II Trial of Cetuximab/Bevacizumab/Irinotecan (CBI) versus Cetuximab/Bevacizumab (CB) in Irinotecan-Refractory Colorectal Cancer. J Clin Oncol 23 (suppl 16s): abstract 3508

    Google Scholar 

  20. Lievre A, Bachet JB, Le Core D, et al. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992–5

    Article  PubMed  CAS  Google Scholar 

  21. Folprecht G, Lutz MP, Schoffski P, et al. (2006) Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17: 450–6

    Article  PubMed  CAS  Google Scholar 

  22. Kim ES, Mauer AM, Tran HT, et al. (2003) A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: final report. Proc Am Soc Clin Oncol 22: abstract 2581

    Google Scholar 

  23. Thienelt CD, Bunn PAJr, Hanna N, et al. (2005) Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 23: 8786–93

    Article  PubMed  Google Scholar 

  24. Robert F, Blumenschein G, Herbst RS, et al. (2005) Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 23: 9089–96

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service ďoncologie médicale, Centre René Gauducheau, Boulevard J. Monod, 44805, Saint-Herblain Cedex

    H. Senellart & J. Bennouna

Authors
  1. H. Senellart
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Bennouna
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag France

About this chapter

Cite this chapter

Senellart, H., Bennouna, J. (2008). Anticorps anti-EGFR. In: Les thérapies ciblées. Oncologie pratique. Springer, Paris. https://doi.org/10.1007/978-2-287-36008-4_2

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-36008-4_2

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-36007-7

  • Online ISBN: 978-2-287-36008-4

Publish with us

Policies and ethics

Search

Navigation